Bridger Management Has Cut Its Nektar Therapeutics (NKTR) Position as Valuation Rose; Commscope Hldg Co (COMM) Stake Maintained by Rivulet Capital Llc

February 13, 2018 - By Pete Kolinski

Roberto Mignone decreased its stake in Nektar Therapeutics (NKTR) by 19.08% based on its latest 2017Q3 regulatory filing with the SEC. Bridger Management Llc sold 536,431 shares as the company’s stock rose 44.66% with the market. The hedge fund run by Roberto Mignone held 2.27 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $54.59M, down from 2.81M at the end of the previous reported quarter. Bridger Management Llc who had been investing in Nektar Therapeutics for a number of months, seems to be less bullish one the $12.10B market cap company. The stock decreased 2.34% or $1.85 during the last trading session, reaching $76.85. About 434,660 shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since February 13, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.

Barry Lebovits increased its stake in Commscope Hldg Co Inc (COMM) by 47.62% based on its latest 2017Q3 regulatory filing with the SEC. Rivulet Capital Llc bought 1.05M shares as the company’s stock declined 6.21% while stock markets rallied. The hedge fund run by Barry Lebovits held 3.25M shares of the technology company at the end of 2017Q3, valued at $107.82 million, up from 2.20 million at the end of the previous reported quarter. Rivulet Capital Llc who had been investing in Commscope Hldg Co Inc for a number of months, seems to be bullish on the $7.12 billion market cap company. The stock increased 0.05% or $0.02 during the last trading session, reaching $37.32. About 385,583 shares traded. CommScope Holding Company, Inc. (NASDAQ:COMM) has risen 25.42% since February 13, 2017 and is uptrending. It has outperformed by 8.72% the S&P500.

Among 12 analysts covering CommScope Holding (NASDAQ:COMM), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. CommScope Holding had 32 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was downgraded by Longbow on Friday, August 4 to “Neutral”. The rating was maintained by Northland Capital with “Hold” on Tuesday, August 8. Raymond James upgraded the shares of COMM in report on Tuesday, February 16 to “Outperform” rating. The rating was initiated by BTIG Research on Friday, June 17 with “Buy”. On Thursday, August 17 the stock rating was upgraded by Morgan Stanley to “Overweight”. The firm has “Market Perform” rating given on Wednesday, September 30 by Northland Capital. Citigroup maintained the stock with “Buy” rating in Thursday, November 2 report. The rating was initiated by Drexel Hamilton with “Buy” on Friday, July 24. Cross Research upgraded the stock to “Buy” rating in Monday, February 22 report. Barclays Capital downgraded the shares of COMM in report on Friday, August 4 to “Hold” rating.

Investors sentiment decreased to 0.72 in Q3 2017. Its down 0.52, from 1.24 in 2017Q2. It worsened, as 61 investors sold COMM shares while 90 reduced holdings. 30 funds opened positions while 78 raised stakes. 191.80 million shares or 0.45% less from 192.66 million shares in 2017Q2 were reported. Jpmorgan Chase And Company has 10.74M shares for 0.08% of their portfolio. First Eagle Investment Llc has 260,000 shares. Wealthtrust holds 336 shares. Fjarde Ap reported 0.04% in CommScope Holding Company, Inc. (NASDAQ:COMM). Blue Harbour LP has invested 4.91% in CommScope Holding Company, Inc. (NASDAQ:COMM). Alliancebernstein Limited Partnership holds 0% of its portfolio in CommScope Holding Company, Inc. (NASDAQ:COMM) for 114,791 shares. Poplar Forest Ltd Llc has 19,875 shares. Kbc Gru Nv has invested 0% in CommScope Holding Company, Inc. (NASDAQ:COMM). Federated Invsts Pa holds 107,746 shares. Dorsal Capital Management Limited Liability Co has 2.15 million shares. Cannell Peter B And Co reported 320,486 shares. Pitcairn invested 0.04% in CommScope Holding Company, Inc. (NASDAQ:COMM). Pnc Group has invested 0% in CommScope Holding Company, Inc. (NASDAQ:COMM). Daiwa Gp accumulated 99,840 shares. James Investment Rech, a Ohio-based fund reported 3,725 shares.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on March, 7. They expect $-0.35 earnings per share, down 25.00% or $0.07 from last year’s $-0.28 per share. After $0.37 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -194.59% negative EPS growth.

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 21 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Overweight” rating given on Thursday, January 7 by Piper Jaffray. The rating was maintained by Roth Capital on Tuesday, May 30 with “Buy”. The rating was maintained by Roth Capital on Monday, November 13 with “Buy”. The rating was maintained by Jefferies with “Buy” on Wednesday, October 18. The rating was downgraded by TheStreet to “Hold” on Wednesday, August 26. Roth Capital maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Wednesday, August 30. Roth Capital has “Buy” rating and $32.5 target. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Roth Capital on Wednesday, August 9. Roth Capital maintained the shares of NKTR in report on Monday, September 21 with “Buy” rating. The company was initiated on Thursday, November 9 by Canaccord Genuity. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Jefferies on Wednesday, November 8.

Investors sentiment decreased to 1.4 in Q3 2017. Its down 0.49, from 1.89 in 2017Q2. It is negative, as 15 investors sold NKTR shares while 52 reduced holdings. 26 funds opened positions while 68 raised stakes. 148.76 million shares or 1.09% more from 147.16 million shares in 2017Q2 were reported. Barclays Plc invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Us National Bank De holds 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 93,340 shares. State Of Tennessee Treasury Department accumulated 135,105 shares. 115,000 were reported by State Of Wisconsin Board. American Group Incorporated has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Invesco Limited stated it has 3.61 million shares or 0.03% of all its holdings. Nationwide Fund has 179,877 shares for 0.02% of their portfolio. Ls Advsrs Limited Liability Company accumulated 5,721 shares. Bridger Mngmt Ltd Liability Company holds 3.27% or 2.27 million shares in its portfolio. Vanguard Group Inc has 14.30 million shares for 0.02% of their portfolio. Schwab Charles Inv owns 703,282 shares. Hightower Advsr Ltd Limited Liability Company reported 36,065 shares. Nelson Van Denburg And Campbell Wealth Mgmt Group Incorporated Ltd Liability Corporation, a Nebraska-based fund reported 500 shares. Dekabank Deutsche Girozentrale reported 0.01% stake. Northwestern Mutual Wealth has 200 shares for 0% of their portfolio.

Since August 16, 2017, it had 0 buys, and 12 selling transactions for $23.49 million activity. Doberstein Stephen K had sold 43,677 shares worth $1.09M. Nicholson John had sold 3,177 shares worth $61,380 on Wednesday, August 16. Shares for $189,575 were sold by Hora Maninder. $139,008 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by CHESS ROBERT. The insider Gergel Ivan P. sold 100,000 shares worth $2.41M. Thomsen Jillian B. also sold $51,159 worth of Nektar Therapeutics (NASDAQ:NKTR) shares.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>